Oncotarget is an integrative conventional scientific and medical journal that provides free access to the most up-to-date academic and clinical research on cancer and experimental treatment analysis. The publication has become so popular among the medical industry and community, Oncotarget has expanded their subject materials to more than just oncology. The fields of study have now broadened to the areas of autophagy, cell destruction, cell cycle, immunology, microbiology, Chromosomes and gerotarget aging. Oncotarget publicizes the most relevant issues and findings every week so that noteworthy discoveries can be revealed without delay to its followers. The main objectives of Oncotarget’s Editors-in-Chief, Mikhail V. Blagosklonny and Andrei V. Gudkov, are included in the following list.
- To augment the influence of research data with insightful review
- To eliminate the boundaries between fields
- To bring together the various fields of biomedical science
- To encourage and advance the application of science and research to combat disease
- Assist all researchers in participating to the progress of science
- To foster ways to live without any diseases
- Freeing the study of oncology from any publication expenses
Oncotarget’s twenty contributing Editorial Board members have vast scientific expertise and backgrounds that belong to the National Academy of Sciences USA and are Nobel Prize and Lasker Award winners. They have published the works of some of the most respect researchers and authors in their fields including Andrew V. Schally, John Reed and Tony Hunter. The different kinds of articles Oncotarget reviews and publishes include commentaries, editorials, research findings, comprehensive reviews and books.
To get a better understanding of the subject matter Oncotarget provides, the titles of a couple of the latest published research papers is, “Next Generation Sequencing of Carcinoma of Unknown Primary Reveals Novel Combinatorial Strategies in a Heterogeneous Mutational Landscape” and “Multiple-Response Regression Analysis Links Magnetic Resonance Imaging Features to De-Regulated Protein Expression and Pathway Activity in Lower Grade Glioma.” Two of the current Editorials are titled, “Functional Proteomic Characterization of Cancer Cell Lines” and “Pharmacologic Targeting of Drug-Induced Enhancers.” Oncotarget is a valuable commodity toward the discovery of cures for cancer, other diseases and anti-aging breakthroughs.